top of page

"Stroke Drug Development:

Expanding the Scope of Acute Drug Therapy"


 STAIR III Sponsors

Abbott Laboratories

AstraZeneca

Aventis

Pharma Bayer AG

Boehringer Ingelheim Pharma, Inc.

Boston Life Sciences

Bristol-Myers Squibb

Centocor

COAXIA

D-Pharm LTD

EKOS Corp.

Eisai Corp. LTD

Eli Lilly & Co.

Elan Pharmaceuticals

Ferrer

Fujisawa Research Institute of America Novo

Nordisk

Glaxo

SmithKline

Hoffmann-LaRoche Inc.

Johnson & Johnson

Mitsubishi Chemical America

PAION

Pfizer Central Research

Radiant Pharma

Schering

AG/Berlex Labs

Suntory Pharmaceutical, Inc.

Texas Biotech

Thrombogenics LTD

Vertex

ViaCell Inc.

Yamanouchi U.S.A.

​

The information contained in this website reflects opinions of STAIR participants regarding the process of conducting research and development into existing, new and prospective drugs and devices for the treatment of stroke. The information is not intended to be a substitute for rigorous independent testing and development of individual compounds and devices by research sponsors, nor should the information and opinions be construed as official government regulations or official interpretations of government regulations. All government regulations and their applications to specific research studies and clinical trials are subject to individual deliberations between study sponsors and government agencies. The information contained in this website is not intended to be a substitute for sound medical advice, clinical judgment or informed treatment decisions.

STAIR® is a Registered Trademark of The Stroke Group.   

© 2025 The Stroke Group

bottom of page